资源类型：
收录情况：
◇ 统计源期刊
◇ 北大核心
◇ CSCD-C
◇ 中华系列
文章类型：
机构：
[1]Department of Pharmacy, Kunming First People's Hospital, Calmette Hospital Affiliated to Kunming Medical University, Kunming, 650051, China
出处：
ISSN：
关键词：
Chloroquine
COVID-19
Cyclophilin
Cyclosporine
Spike protein
摘要：
The outbreak of COVID-19 has infected millions of people and caused hundreds of thousands of deaths worldwide. As there is no specific medicines or effective vaccines against 2019-nCoV at present, it is an alternative strategy to repurpose existing drugs for new diseases. Cyclosporin A inhibits the replication of coronaviruses by binding to cellular cyclophilins. Chloroquine/hydroxychloroquine can block virus-receptor binding through interfering with terminal glycosylation of the cellular receptor angiotensin-converting enzyme 2 (ACE2). Trastuzumab prevents the binding of IL-6 to both sIL-6R and mIL-6R and thereby inhibits the cytokine storm syndrome induced by COVID-19. This paper discussed the potential anti-2019-nCoV effects of some common immunosuppressant including cyclosporine, chloroquine/hydroxychloroquine, and tocilizumab. Copyright © 2020 by the Chinese Medical Association.
第一作者：
第一作者机构：
[1]Department of Pharmacy, Kunming First People's Hospital, Calmette Hospital Affiliated to Kunming Medical University, Kunming, 650051, China
通讯作者：
推荐引用方式(GB/T 7714)：
Song W,Li X,Bao J,等.免疫抑制剂在COVID-19患者中的潜在应用价值[J].Chinese Journal of Microbiology and Immunology (China).2020,40(7):
